CRISPR renders prostate cancer susceptible to immunotherapy
Novel RNA targeting technology strips prostate tumors of their immune defenses.
1Immunotherapy hurdle in prostate cancer
Prostate tumors are typically 'immune cold' as they fail to attract sufficient T cells. This prevents the immune system from fighting cancer effectively. While conventional immunotherapies prove ineffective, the new CRISPR-based approach aims to break this resistance.
2Link between mRNA shortening and cancer
Researchers discovered 12 years ago that mRNAs in tumor cells were abnormally short. This truncation leads to overproduction of SPSB1 protein, which destroys the MHC-1 complex. Without MHC-1, T cells cannot recognize the tumor.
3Innovative use of CRISPR Cas13
A team led by Duke University developed a CRISPR Cas13 system that regulates mRNA length instead of cutting DNA. This method successfully prevented cancer cells from shortening mRNA, thereby reducing SPSB1 protein production.
4Promising results in mouse models
The study published in Nature Biomedical Engineering showed restored MHC-1 complexes in treated mice. This reactivated immune checkpoint therapy, allowing more T cells to infiltrate tumors and effectively destroy cancer cells.
5Treatment with no detectable side effects
Researchers confirmed the CRISPR intervention didn't affect any genetic material beyond the target mRNA. This finding strengthens the treatment's safety profile, marking a critical milestone before human trials.
6New hope for pancreatic cancer
With funding from Wilmot Cancer Institute, the technology will now be tested against pancreatic cancer. If successful, it could pioneer new treatments for other immunotherapy-resistant 'cold' tumors.